share_log

Biodesix Sees Q4 Revenues Of $20.4M And FY24 Revenues Of $71.3M Vs. $70.73M Estimate

Biodesix Sees Q4 Revenues Of $20.4M And FY24 Revenues Of $71.3M Vs. $70.73M Estimate

Biodesix預計第四季度收入爲2040萬美元,2024財年收入爲7130萬美元,而估計爲7073萬美元。
Benzinga ·  01/10 11:06
  • Total revenue is estimated to be $20.4 million and $71.3 million for the fourth quarter and fiscal 2024, respectively, an increase of 39% and 45% over the respective prior year comparable periods;
    • Lung Diagnostics revenue is estimated to be $17.2 million and $64.7 million for the fourth quarter and fiscal 2024, respectively, an increase of 34% and 43% over the respective prior year comparable periods;
    • Biopharma Services and other revenue is estimated to be $3.2 million and $6.6 million for the fourth quarter and fiscal 2024, respectively, an increase of 68% and 69% over the respective prior year comparable periods; entering 2025 with $12.2 million under contract but not yet recognized as revenue, a 54% increase over the prior year comparable period;
  • Lung Diagnostic test volumes of 14,600 and 54,300 for the fourth quarter and fiscal 2024, respectively, an increase of 34% and 40% over the respective prior periods;
  • Cash and cash equivalents of $26.2 million as of December 31, 2024.
  • 預計第四季度和2024財年的總營業收入分別爲2040萬美元和7130萬美元,比前一年同期增長39%和45%;
    • 肺部診斷的營業收入預計在2024財年的第四季度爲1720萬美金,全年爲6470萬美金,分別比去年同期增長34%和43%。
    • 生物製藥服務及其他營業收入預計在2024財年的第四季度爲320萬美金,全年爲660萬美金,分別比去年同期增長68%和69%;進入2025年,合同金額爲1220萬美金,但尚未確認作爲營業收入,比去年同期增長54%。
  • 肺部診斷測試量分別爲14600和54300,在2024財年的第四季度和整年,分別比去年同期增長34%和40%。
  • 截至2024年12月31日的現金及現金等價物爲2620萬美金。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論

    聲明

    本頁的譯文內容由軟件翻譯。富途將竭力但卻不能保證翻譯內容之準確和可靠,亦不會承擔因任何不準確或遺漏而引起的任何損失或損害。